Skip to content

Antibacterial Effect of Nano Silver Fluoride vs Chlorhexidine on Occlusal Carious Molars Treated With Partial Caries Removal Technique

Evaluation of the Antibacterial Effect of Nano Silver Fluoride Versus Chlorhexidine on Occlusal Carious Molars Treated With Partial Caries Removal Technique: A Randomized Clinical Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03186261
Enrollment
44
Registered
2017-06-14
Start date
2018-04-01
Completion date
2018-12-28
Last updated
2021-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dental Caries

Brief summary

* The teeth of the patients that meet inclusion criteria will be anesthetized, isolated with a rubber dam. * Cavity opened using conventional high-speed rotary instruments. * The central cariogenic biomass and the superficial parts of the necrotic dentine will be removed with round burs. * Caries lesion will be completely removed in the enamel/dentin junction. * The excavation procedure will be terminated as soon as the soft and wet dentine was removed and the remaining tissue was leathery but not hard on exploring. * A dentinal sample will then be collected from the base of the cavity using sterile spoon excavator as a baseline for bacteriological assessment. * Then, application of either intervention or control agent, another dentinal sample will be collected using a sterile excavator and transferred into sterile tubes and transferred to the laboratory for microbiological analysis. * Filling of the cavity with resin composite restoration. * All clinical procedures will be carried out at the same visit.

Detailed description

I.1. Study setting This clinical study will be held in the Clinic of Conservative Dentistry Department, Faculty of Dentistry, Cairo University, Egypt. The researcher will bear ultimate responsibility for all activities associated with the conduct of a research project including recruitment of patients, explaining and performing the procedures to them. II.4.a Excavation protocol: The teeth of the patients that meet inclusion criteria will be anesthetized, isolated with a rubber dam. Cavity opened using conventional high-speed rotary instruments. The central cariogenic biomass and the superficial parts of the necrotic dentine will be removed with round burs. Caries lesion will be completely removed in the enamel/dentin junction. The excavation procedure will be terminated as soon as the soft and wet dentine was removed and the remaining tissue was leathery but not hard on exploring. A dentinal sample will then be collected from the base of the cavity using sterile spoon excavator as a baseline for bacteriological assessment. Then, application of either intervention or control agent, another dentinal sample will be collected using a sterile excavator and transferred into sterile tubes and transferred to the laboratory for microbiological analysis. II.4.b Assessment of Outcome: Samples of carious dentine will be collected with sterile excavator before and after application of intervention/control agent. The dentine samples will be transferred to sterile container containing a 1mL thioglycollate medium used as a carrier, then this sterile container will be kept in an ice box and taken to the microbiology laboratory for processing, within an hour, by another examiner who is blinded to the type of agent applied after partial caries removal. Samples will be vortexed for two minutes, decimally diluted and 0.1 ml will be plated on Mitis Salivarius Bacitracin agar plates, these plates will be incubated anaerobically for 48 hour at 37ºC then aerobically for 24 hour at room temperature. The number of colonies will be expressed as colony-forming units (CFU/ml) compared before and after application of the antibacterial agent. II.5. Participant timeline: All clinical procedures will be carried out at the same visit. II.6. Sample size calculation: The aim of this study is to evaluate the antibacterial action Nano Silver Fluoride solution application in comparison to Chlorhexidine solution after partial caries removal in class I carious permanent molar. Based on a previous study by Mohan et al. 20165, the expected difference between two interventions is expected to be 2.1±2.2CFU/mL × 103. Using power 80% and 5% significance level we will need to study 18 in each group to be able to reject the null hypothesis that the population means of the experimental and control groups are equal. This number is to be increased to 22 patients in each group to compensate for possible losses during follow up. The sample size was calculated by PS program. II.7. Recruitment: Patients will be recruited from outpatient clinic of Conservative Dentistry Department in Faculty of Dentistry, Cairo University; after explaining the benefits/risks from the application of the interventions, then eligible patients will be recruited to fulfil the eligibility criteria according to participant timeline. II.8.a. Recruitment Strategy: The patients will be subjected to full examination and diagnosis using dental charts. Once the patients that are potentially eligible for this study are identified, they will be contacted by the researcher who will explain the study and ascertains the patient's interest. If interested, more detailed evaluations and preparations are made. II.9. Randomization and assignment of interventions: II.9.a. Allocation sequence generation: The allocation sequence will be generated using (www.randomization.com). II.9.b. Allocation concealment mechanism: The randomization unit was the tooth, and the randomization procedure will be performed as follows. A number corresponding to each treatment group will be printed on pieces of paper and kept in dark containers. A paper will be selected from the container by a person other than the operator, and the treatment indicated will be performed (intervention/control). Blinding of the operator is not possible, because the color of intervention and control solution is different. The operator is blinded until randomization into groups, to avoid biases with regard to the application of antibacterial agent. Also, the examiner who will carry the microbiological analysis of dentin samples will be blinded to the type of agent applied during treatment. Finally, the treatment results will be assessed blindly by a statistician. II.9.c. Implementation: Dr. Mai Mamdouh (co-supervisor) will perform the allocation sequence and assign the participants to the intervention/Control treatment group. II.9.d. Blinding: The side to which interventions or control is assigned to will be recorded and all records of all patients will be kept with the main supervisor. Blinding of the operator is not possible, because the color of intervention and control solution is different. The operator is blinded until randomization into groups, to avoid biases with regard to the application of antibacterial agent. Also, the examiner who will carry the microbiological analysis of dentin samples will be blinded to the type of agent applied during treatment. Finally, the treatment results will be assessed blindly by a statistician. II.10. Data collection methods: \*Baseline data collection: For every patient medical history, dental history and examination charts will be filled by the operator. The report will be anonymous where patients identified by their serial numbers (the first letter of the first and last name and date of birth) only will be registered. Full detailed personal data of the patient will be written in separate sheet having the patient's serial number for further contact with patient. \*Outcome data collection: The results will be converted into a table to facilitate the description of the results. The microbiological analysis will be performed blindly in relation to the type of solution applied after partial caries removal. II.11.Data management: The data will be entered and stored on a personal computer. Double data entry will be saved on an external hard disc to prevent loss of data. II.12. Statistical methods: Data will be analyzed using IBM SPSS advanced statistics (Statistical Package for Social Sciences), version 21 (SPSS Inc., Chicago, IL). Numerical data will be described as mean and standard deviation or median and range. Categorical data will be explored for normality using Kolmogrov-Smirnov test and Shapiro-Wilk test. Comparisons between two groups for normally distributed numeric variables will be done using the Student's t-test while for non normally distributed numeric variables will be done by Mann-Whitney test. Comparisons between categorical variables will be performed using the chi square test. A p-value less than or equal to 0.05 will be considered statistically significant. All tests will be two tailed. II.13. Monitoring: II.13.a. Data monitoring: The main supervisor will monitor this study. His role is to monitor any risk of bias could be done from participants, operator or assessors. Also to monitor blinding of the assessors and patient safety, outstanding benefits or harms. II.13.b. Harms: The main supervisor should inform participants about the possible harms, if present. Participants are allowed to contact the operator at moment through telephone. In case of accidental pulp exposure during excavation , emergency access cavity and pulp extirpation will be done by the operator and then the patient will be referred to Endodontic Department clinic to complete the rool canal treatment. II.13.c. Auditing: In the present trial, auditing will be done by the main and co-supervisors to assure quality of the research frequency procedures. II.14. Ethics and dissemination II.14.a. Research ethics approval: Application forms for carrying out the clinical trial, checklist and informed consent of Research Ethics Committee (REC) Faculty of Dentistry, Cairo University will be retrieved and filled, then will be delivered for (REC) committee for approval. This is done to prevent any ethical problems during the study or any harm for any of the participants. II.14.b. Protocol amendments: If a new protocol will be used a protocol amendment will be submitted; containing a new copy of the new protocol and brief explanation about the differences between it and the previous protocols. If there is a change in the existing protocol that affects safety of subjects, investigation scope or scientific quality of the trial, an amendment containing a brief explanation about the change will be submitted. If a new author will be added to accomplish the study, an amendment including the investigator's data and qualifications to conduct the investigation will be submitted to prevent ghost authorship. II.14.c. Consent: The operator (Ali Mostafa Shamaa) is responsible for admitting and signing the written consents during the enrolment day. II.15. Confidentiality: Name, personal data and pictures of the participants will not appear on the protocol form and will be maintained secured for 10 years after the trial. This is done for protection of participants' privacy and civil rights. II.16. Declaration of interests: There is no conflict of interest, no funding or material supplying from any parties. Access to final data will be allowed to the operator ,the main and co-supervisors of the study who are not involved in assessment of the outcome. II.18. Ancillary and post-trial care: Patients will be followed up after the application after 3, 6 months. II.19. Dissemination policy: Full protocol will be published online in www.clinicaltrials.gov to avoid repetition and to keep the integrity of the research work. Thesis will be discussed in front of judgment committee. The study will be published to report the results of this clinical trial.

Interventions

Nano silver fluoride that composed of silver nanoparticles, chitosan and fluoride that combines preventive and antimicrobial properties.

DRUGCavity Cleanser

Moistens dentin surface after cavity preparation using a micro brush.

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Inclusion Criteria of participants: 1. Not received antibiotic therapy since 1 month before sampling. 2. Good oral hygiene. 3. Co-operative patients approving the trial. * Inclusion Criteria of teeth: 1. Class I deep caries lesions in permanent molar (reaching ≥ 1/2 of the dentin on radiographic examination). 2. Absence of spontaneous pain; negative sensitivity to percussion; and absence of periapical lesions (radiographic examination).

Exclusion criteria

*

Design outcomes

Primary

MeasureTime frameDescription
Bacterial Count of Streptococus Mutans5 minutes on average between baseline and after application of the solutionDigital Colony Counter, Agar Diffusion test

Countries

Egypt

Participant flow

Participants by arm

ArmCount
Nano Silver Fluoride Solution
Nano silver fluoride solution (Prepared in Nanotech Co., Egypt) based on silver nanoparticles, chitosan and fluoride. Each tooth will receive two drops of NSF with a micro brush, equivalent to a dose of 10 mg of the solution. Nano silver fluoride solution: Nano silver fluoride that composed of silver nanoparticles, chitosan and fluoride that combines preventive and antimicrobial properties.
22
Cavity Cleanser
Chlorhexidine digluconate 2 % solution (Cavity Cleanser, Bisco, USA). Each tooth will receive two drops of cavity cleanser with a micro brush, equivalent to a dose of 10 mg of the solution. Cavity Cleanser: Moistens dentin surface after cavity preparation using a micro brush.
22
Total44

Baseline characteristics

CharacteristicCavity CleanserTotalNano Silver Fluoride Solution
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
22 Participants44 Participants22 Participants
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
Egypt
22 participants44 participants22 participants
Sex: Female, Male
Female
14 Participants30 Participants16 Participants
Sex: Female, Male
Male
8 Participants14 Participants6 Participants
Vital Permanent molar with deep occlusal carious lesion22 Teeth44 Teeth22 Teeth

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 220 / 22
other
Total, other adverse events
0 / 220 / 22
serious
Total, serious adverse events
0 / 220 / 22

Outcome results

Primary

Bacterial Count of Streptococus Mutans

Digital Colony Counter, Agar Diffusion test

Time frame: 5 minutes on average between baseline and after application of the solution

ArmMeasureGroupValue (MEAN)Dispersion
Nano Silver Fluoride SolutionBacterial Count of Streptococus MutansBaseline2.00 CFU/ml log10Standard Deviation 0.33
Nano Silver Fluoride SolutionBacterial Count of Streptococus MutansAfter solution application1.12 CFU/ml log10Standard Deviation 0.59
Cavity CleanserBacterial Count of Streptococus MutansBaseline2.04 CFU/ml log10Standard Deviation 0.23
Cavity CleanserBacterial Count of Streptococus MutansAfter solution application1.05 CFU/ml log10Standard Deviation 0.63

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026